Yes, Rybelsus (oral semaglutide) remains available for treatment
Rybelsus is currently FDA-approved and available in the United States for the treatment of type 2 diabetes in adults. 1
Current Formulations and Availability
Rybelsus is available in multiple formulations:
Original Formulation
- 3 mg, 7 mg, and 14 mg tablets for type 2 diabetes management 1
- Taken once daily on an empty stomach with up to 4 oz (120 mL) of water
- Must wait at least 30 minutes before eating, drinking, or taking other medications
New R2 Formulation
- 1.5 mg, 4 mg, and 9 mg tablets (newer formulation designated as "Formulation R2") 1
- FDA labeling explicitly notes: "Individual strengths of Rybelsus are not substitutable on a mg-to-mg basis" between formulations
- This indicates ongoing product development and market availability
Clinical Context from Guidelines
The 2025 American Diabetes Association Standards of Care explicitly recognize GLP-1 receptor agonists are available in both subcutaneous and oral formulations 2. The guidelines classify GLP-1 RAs (including oral formulations) as having:
- High to very high glucose-lowering efficacy
- No hypoglycemia risk
- Intermediate to very high weight loss effects
- Cardiovascular benefits (demonstrated for dulaglutide, liraglutide, and semaglutide)
- Renal benefits for albuminuria outcomes
- No dose adjustment required for dulaglutide, liraglutide, or semaglutide in renal impairment 2
Important Prescribing Considerations
Administration Requirements
The oral formulation requires specific dosing conditions due to low bioavailability (~1% vs. 89% for subcutaneous) 3:
- Empty stomach upon waking
- Limited water intake (≤4 oz)
- 30-minute wait before food or other medications
- These requirements may affect concomitant medication absorption 4, 5
Clinical Efficacy
Recent evidence demonstrates oral semaglutide 50 mg achieves -15.1% body weight reduction at 68 weeks, comparable to subcutaneous semaglutide 2.4 mg (-14.9%) 3. The PIONEER 6 trial confirmed cardiovascular safety with significant reductions in cardiovascular and overall mortality 6.
Patient Selection
Oral semaglutide is particularly appropriate for:
- Patients with inadequate glycemic control on metformin or other oral agents
- Those requiring weight loss
- Patients at risk for hypoglycemia
- Needle-averse patients who would otherwise avoid GLP-1 RA therapy 4, 5, 3
Contraindications and Warnings
Absolute contraindications include:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Pregnancy (discontinue at least 2 months before planned pregnancy) 1, 4
Use caution or avoid in:
- History of pancreatitis
- High risk for gallbladder disease
- Gastroparesis
- Those at high risk for diabetic retinopathy (close monitoring required) 2
Emerging Safety Signals
A 2026 case report documented deep venous thrombosis within two weeks of initiating oral semaglutide in an adolescent, though causality remains uncertain 7. Clinicians should maintain vigilance, particularly with off-label use for weight loss in younger patients.
The presence of SNAC (absorption enhancer) in breast milk with unknown effects on infants means breastfeeding is not recommended during Rybelsus treatment 1.
Rybelsus remains a fully available, FDA-approved treatment option with expanding formulations, supported by current diabetes management guidelines and robust clinical evidence. 2, 1